1341 related articles for article (PubMed ID: 32098487)
1. Psychedelics and Psychedelic-Assisted Psychotherapy.
Reiff CM; Richman EE; Nemeroff CB; Carpenter LL; Widge AS; Rodriguez CI; Kalin NH; McDonald WM;
Am J Psychiatry; 2020 May; 177(5):391-410. PubMed ID: 32098487
[TBL] [Abstract][Full Text] [Related]
2. [Psychotherapy with Adjuvant use of Serotonergic Psychoactive Substances: Possibilities and Challenges].
Majić T; Jungaberle H; Schmidt TT; Zeuch A; Hermle L; Gallinat J
Fortschr Neurol Psychiatr; 2017 Jul; 85(7):383-392. PubMed ID: 28768346
[No Abstract] [Full Text] [Related]
3. The Psychedelic Future of Post-Traumatic Stress Disorder Treatment.
Zaretsky TG; Jagodnik KM; Barsic R; Antonio JH; Bonanno PA; MacLeod C; Pierce C; Carney H; Morrison MT; Saylor C; Danias G; Lepow L; Yehuda R
Curr Neuropharmacol; 2024; 22(4):636-735. PubMed ID: 38284341
[TBL] [Abstract][Full Text] [Related]
4. Psychedelic drugs-a new era in
psychiatry?
.
Nutt D
Dialogues Clin Neurosci; 2019; 21(2):139-147. PubMed ID: 31636488
[TBL] [Abstract][Full Text] [Related]
5. Psychedelics: Alternative and Potential Therapeutic Options for Treating Mood and Anxiety Disorders.
Lowe H; Toyang N; Steele B; Grant J; Ali A; Gordon L; Ngwa W
Molecules; 2022 Apr; 27(8):. PubMed ID: 35458717
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of psychedelics for the treatment of mental disorders: A systematic review and meta-analysis.
Yao Y; Guo D; Lu TS; Liu FL; Huang SH; Diao MQ; Li SX; Zhang XJ; Kosten TR; Shi J; Bao YP; Lu L; Han Y
Psychiatry Res; 2024 May; 335():115886. PubMed ID: 38574699
[TBL] [Abstract][Full Text] [Related]
7. Adverse events in clinical treatments with serotonergic psychedelics and MDMA: A mixed-methods systematic review.
Breeksema JJ; Kuin BW; Kamphuis J; van den Brink W; Vermetten E; Schoevers RA
J Psychopharmacol; 2022 Oct; 36(10):1100-1117. PubMed ID: 36017784
[TBL] [Abstract][Full Text] [Related]
8. [Efficacy of psychedelics in psychiatry, a systematic review of the literature].
Berkovitch L; Roméo B; Karila L; Gaillard R; Benyamina A
Encephale; 2021 Aug; 47(4):376-387. PubMed ID: 33888297
[TBL] [Abstract][Full Text] [Related]
9. Psychedelic drugs for psychiatric disorders.
da Costa SC; Oesterle T; Rummans TA; Richelson E; Gold M
J Neurol Sci; 2022 Sep; 440():120332. PubMed ID: 35841696
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of Psychoactive Drugs for the Treatment of Posttraumatic Stress Disorder: A Systematic Review of MDMA, Ketamine, LSD and Psilocybin.
Varker T; Watson L; Gibson K; Forbes D; O'Donnell ML
J Psychoactive Drugs; 2021; 53(1):85-95. PubMed ID: 32931403
[TBL] [Abstract][Full Text] [Related]
11. Psychedelic medicines for mood disorders: current evidence and clinical considerations.
Sarris J; Pinzon Rubiano D; Day K; Galvão-Coelho NL; Perkins D
Curr Opin Psychiatry; 2022 Jan; 35(1):22-29. PubMed ID: 34855694
[TBL] [Abstract][Full Text] [Related]
12. Older adults in psychedelic-assisted therapy trials: A systematic review.
Bouchet L; Sager Z; Yrondi A; Nigam KB; Anderson BT; Ross S; Petridis PD; Beaussant Y
J Psychopharmacol; 2024 Jan; 38(1):33-48. PubMed ID: 38240068
[TBL] [Abstract][Full Text] [Related]
13. United States National Institutes of Health grant funding for psychedelic-assisted therapy clinical trials from 2006-2020.
Barnett BS; Parker SE; Weleff J
Int J Drug Policy; 2022 Jan; 99():103473. PubMed ID: 34624734
[TBL] [Abstract][Full Text] [Related]
14. Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: a systematic review of systematic reviews.
Dos Santos RG; Bouso JC; Alcázar-Córcoles MÁ; Hallak JEC
Expert Rev Clin Pharmacol; 2018 Sep; 11(9):889-902. PubMed ID: 30102078
[TBL] [Abstract][Full Text] [Related]
15. Psychedelic renaissance: Revitalized potential therapies for psychiatric disorders.
Rhee TG; Davoudian PA; Sanacora G; Wilkinson ST
Drug Discov Today; 2023 Dec; 28(12):103818. PubMed ID: 37925136
[TBL] [Abstract][Full Text] [Related]
16. Analysis of recreational psychedelic substance use experiences classified by substance.
Hase A; Erdmann M; Limbach V; Hasler G
Psychopharmacology (Berl); 2022 Feb; 239(2):643-659. PubMed ID: 35031816
[TBL] [Abstract][Full Text] [Related]
17. The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Report: Serotonergic Psychedelic Treatments for Major Depressive Disorder.
Rosenblat JD; Husain MI; Lee Y; McIntyre RS; Mansur RB; Castle D; Offman H; Parikh SV; Frey BN; Schaffer A; Greenway KT; Garel N; Beaulieu S; Kennedy SH; Lam RW; Milev R; Ravindran AV; Tourjman V; Ameringen MV; Yatham LN; Taylor V
Can J Psychiatry; 2023 Jan; 68(1):5-21. PubMed ID: 35975555
[TBL] [Abstract][Full Text] [Related]
18. Dosing Psychedelics and MDMA.
Liechti ME; Holze F
Curr Top Behav Neurosci; 2022; 56():3-21. PubMed ID: 34734392
[TBL] [Abstract][Full Text] [Related]
19. Psychedelic Therapy: A Primer for Primary Care Clinicians-Historical Perspective and Overview.
Tabaac BJ; Shinozuka K; Arenas A; Beutler BD; Cherian K; Evans VD; Fasano C; Muir OS
Am J Ther; 2024 Mar-Apr 01; 31(2):e97-e103. PubMed ID: 38518266
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic role of psilocybin and 3,4-methylenedioxymethamphetamine in trauma: A literature review.
Fonseka LN; Woo BK
World J Psychiatry; 2023 May; 13(5):182-190. PubMed ID: 37303932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]